A Study of NTX-1472 in Social Anxiety Disorder
Start Date
12/9/2025
Completion Date
1/1/2027
Summary
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
NTX-1472
Placebo
Conditions
Locations
SOAR Clinical Study Site
Encino, California 91316
United States
SOAR Clinical Study Site
Los Angeles, California 90025
United States
SOAR Clinical Study Site
Oceanside, California 92056
United States
SOAR Clinical Study Site
San Jose, California 95124
United States
SOAR Clinical Study Site
Jacksonville, Florida 32256
United States
SOAR Clinical Study Site
Tampa, Florida 33615
United States
SOAR Clinical Study Site
Boston, Massachusetts 02131
United States
SOAR Clinical Study Site
Las Vegas, Nevada 89119
United States
SOAR Clinical Study Site
Brooklyn, New York 11229
United States
SOAR Clinical Study Site
Memphis, Tennessee 38119
United States
SOAR Clinical Study Site
Austin, Texas 78737
United States